Department of Hemato Oncology Faculty of Medicine and Dentistry Palacký University Olomouc and University Hospital Olomouc Olomouc Czech Republic

Department of Internal Medicine Hematology and Oncology Masaryk University Brno Czech Republic; Department of Internal Medicine Hematology and Oncology University Hospital Brno Brno Czech Republic

Zobrazit více v PubMed

Hills RK, Castaigne S, Appelbaum FR, et al. . Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15(9):986-996. PubMed PMC

Lambert J, Pautas C, Terré C, et al. . Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica. 2019;104(1):113-119. PubMed PMC

Stone RM, Mandrekar SJ, Sanford BL, et al. . Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454-464. PubMed PMC

European Medicines Agency/Rydapt (midostaurin). https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt Accessed September 20, 2022.

European Medicines Agency/Mylotarg (gemtuzumab ozogamicin). https://www.ema.europa.eu/en/medicines/human/EPAR/mylotarg-0 Accessed September 20, 2022.

Röllig C, Schliemann C, Mikesch JH, et al. . Gemtuzumab ozogamicin plus midostaurin in combination with standard intensive induction therapy in newly diagnosed AML: results from a phase-I study. Blood. 2021;138(Suppl 1):2324. PubMed

Borate U, Kaempf A, Minnier J, et al. . FLT3-mutated acute myeloid leukemia using a novel regimen of gemtuzumab ozogamicin and midostaurin in combination with standard cytarabine and daunorubicin induction therapy. Blood. 2021;138(Suppl 1):1269. PubMed

Russell N, Wilhelm-Benartzi C, Othman J, et al. . Gemtuzumab-based induction chemotherapy combined with midostaurin for FLT3 mutated AML. Results from the NCRI AML19 “MIDOTARG” pilot trial. Hemasphere. 2022;6(s126):27-28.